Sanfilippo Syndrome Type A

1
Pipeline Programs
2
Companies
8
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

GC Biopharma
GC BiopharmaKorea - Yongin
1 program
1
GC1130APhase 11 trial
Active Trials
NCT06567769RecruitingEst. Jun 2027
Takeda
TakedaTOKYO, Japan
1 program
assessmentN/A5 trials
Active Trials
NCT06252493Recruiting25Est. Dec 2029
NCT04938440Completed536Est. Feb 2023
NCT03409796Completed16Est. May 2019
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
GC BiopharmaGC1130A
Takedaassessment
Takedaassessment
Takedaassessment
Takedaassessment
Takedaassessment
Takedaassessment
Takedaassessment

Clinical Trials (8)

Total enrollment: 689 patients across 8 trials

Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA)

Start: Nov 2024Est. completion: Jun 2027
Phase 1Recruiting

Taste Assessment Study of SHP429 in Healthy Adult Subjects

Start: Jun 2014Est. completion: Jun 201418 patients
Phase 1Completed

Value of PET/MR Enterography in the Assessment of Crohn's Disease Using a Collagen-binding Radiotracer.

Start: Dec 2023Est. completion: Dec 202925 patients
N/ARecruiting

Assessment of Updated Educational Materials for Instanyl®

Start: Feb 2022Est. completion: Feb 2023536 patients
N/ACompleted

Assessment of Immune Activation and Tolerance in Celiac Disease During Gluten Challenge

Start: Apr 2018Est. completion: May 201916 patients
N/ACompleted

Sophisticated Assessment of Disease Burden in Patients With Fabry Disease

Start: Oct 2010Est. completion: Sep 201336 patients
N/ACompleted

A Study of Patients With Sanfilippo Syndrome Type A (MPS IIIA)

Start: Feb 2010Est. completion: Jul 201325 patients
N/ACompleted

Screening Study to Identify Pediatric Patients With Hunter Syndrome Who Demonstrate Evidence of Central Nervous System (CNS) Involvement and Who Are Currently Receiving Treatment With Elaprase®

Start: Jul 2009Est. completion: Jul 201133 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 689 patients
2 companies competing in this space